Vaccine Efficacy Against Variants of Covid-19

vaccine efficacy

Prof. Wiku Adisasmito, spokesman for the Covid-19 Handling Task Force, revealed that the total Beta variant in Indonesia was 17 cases, the Alpha variant reached 64 cases, and the Delta variant with 2,240 cases. It is known that the delta variant dominates almost all provinces of Indonesia. Wiku said that there is still a possibility that the vaccine efficacy will decrease against the new Corona variant.

“Even though it’s decreasing, people don’t need to worry especially about the five types of vaccines that have been used in Indonesia. The World Health Organization (WHO) has confirmed that standard vaccines with good immunity-forming ability are those that have efficacy or effectiveness above 50 percent,”

said Prof. Wiku.

It is known that Indonesia uses the AstraZeneca, Pfizer, Moderna, Sinovac, and Sinopharm vaccines.

Quoted from, the following is a list of the effectiveness of the five vaccines against the Covid-19 variant.

For the Alpha variant, the Sinovac vaccine has an efficacy above 50 percent. As for the virus variant from Wuhan, the five vaccines above each have efficacy above 50 percent. This figure is the threshold set by the World Health Organization (WHO).

Three of the five types of Covid-19 vaccines in Indonesia have proven to be able to fight the Alpha variant with efficacy above 50 percent, namely Moderna, AstraZeneca, and Pfizer. While Sinovac and Sinopharm still need further studies for their effectiveness. This condition is also found in the Beta variant.

The AstraZeneca and Pfizer vaccines have effectiveness above 50 percent on the Delta variant in Indonesia. Meanwhile, the types of vaccines that still require further studies on their effectiveness in the Delta variant are Sinovac and Moderna. The Sinopharm vaccine is still being studied further to treat the Delta variant.

For the Gamma variant, the Sinovac vaccine is a formidable opponent. While AstraZeneca, Pfizer, and Moderna still need further studies for this variant virus. Meanwhile, Sinopharm is still waiting for the results of the study.